Hemgenix has become offered ‘conditional authorisation’. Consequently the European Medicines Agency decided that the key benefits of Hemgenix are greater than its challenges, but the business will have to present more proof after authorisation. Based on the clinical specialists consulted by CADTH, there are many unmet needs for hemophilia B. https://grahamu123gfd3.wikilima.com/user